A new partnership for the preclinical development of anticancer drug candidates and clinical sample production

▲ From left: Koo Lee PhD, CEO of Therapex, Steve Yang, Co-CEO of WuXi AppTec, and Cho Seokyoung, General Manager of WuXi AppTec.

Therapex announced on the 6^th that it has signed a comprehensive memorandum of understanding (MOU) with WuXi AppTec, a global contract development and manufacturing organization (CDMO), for the development of immunotherapeutic and targeted anticancer drugs.

Under this agreement, WuXi AppTec will provide services necessary for Therapex's preclinical research, clinical sample production, and submission of Investigational New Drug (IND) applications for novel anticancer drugs currently in development, with Therapex aiming to initiate clinical trials next year. The partnership is expected to continue in the future, encompassing lead compound discovery and efficacy evaluations.

Established in 2020 by Gradient (formerly Interpark), Therapex is a new drug development company involved in projects for immunotherapeutic agents, targeted anticancer agents, and proteolysis-targeting chimeras (TPD), having rebranded from 'Interpark Bioconvergence' to 'Therapex.'

Therapex has also recently welcomed Myoungki Baek PhD, a new drug development expert from SK Biopharmaceuticals, as Managing Director to expedite the preclinical development of its new drug candidates.

Koo Lee PhD, CEO of Therapex, commented, "Through this agreement, we believe that WuXi AppTec's global capability in new drug development, as well as their extensive experience in efficient project management, will enable streamlined preclinical development. We will thus be able to accelerate the development of new anticancer drugs, targeting cancers that have significant medical unmet needs."

Steve Yang, Co-CEO of WuXi AppTec, expressed his intentions, stating, "Building upon WuXi AppTec's expertise in targeted anticancer agents and diverse experience in new drug development, we aim to contribute to the successful development of Therapex's new anticancer drugs."

Reporter: Kim Sungmin sungmin.kim@bios.co.kr

Press releases and article submissions press@bios.co.kr

Source : http://www.biospectator.com/view/news_view.php?varAtcId=17365